Posted in | News | Mining Business

Perseus Declares Acquiring Interest in OreCorp Perth

As a strategic equity investment, Perseus Mining Limited has declared that it has obtained a significant stake of 15.03% in shares of OreCorp Limited.

Businessmen making handshake with partner,

Image Credit: TippaPatt/Shutterstock.com

The ASX lists OreCorp, an upcoming mineral development company, with the code ORR. The Nyanzaga Gold Project is OreCorp’s primary pre-development project in northwest Tanzania. It has a stated Probable Ore Reserve of 40.08 Mt @ 2.02 g/t gold, or 2.60 million ounces of gold.

Perseus and OreCorp are not currently engaged in conversations. Perseus has no plans to propose a change of control transaction that would compete with the existing plan that Silvercorp Metals Inc. is offering OreCorp shareholders.

Nonetheless, Perseus would be happy to speak with OreCorp to figure out the best and quickest course of action for advancing the Nyanzaga Gold Project.

At the OreCorp scheme meeting on Friday, December 8th, 2023, Perseus plans to vote against the Silvercorp Scheme.

The Form 603 Notice of Initial Substantial Holder, which will be filed on the ASX platform, will contain further information about the OreCorp Share Acquisition.

Perseus continues to assess and, where considered commercially appropriate, deploy its reserves of cash, bullion, and undrawn debt facilities totaling approximately US$900 million, to pursue opportunities that complement its existing asset portfolio and our organic growth program. Acquiring the 15.03% interest in OreCorp via this share acquisition is a strategic investment for Perseus.

Jeff Quartermaine, Executive Chairman, Perseus Mining Limited

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.